Sacituzumab Govitecan-hziy for Breast Cancer (TROPiCS-02 Trial)

"Sacituzumab Govitecan-hziy is not only useful for patients that have undergone adjuvant anthracycline-containing therapy, but also those suffering from conditions like soft tissue sarcoma (sts), colorectal carcinoma, and malignant neoplasms."

"This particular study is not recruiting patients at this time. However, the trial was active from May 8th, 2019 to November 3rd, 2022. If you are looking for other trials, there are 2380 breast cancer studies and 866 Sacituzumab Govitecan-hziy studies that are still actively enrolling patients."

"At the moment, this trial is being conducted at 58 different sites which are situated in cities such as Kansas City, Minneapolis and Miami. There are also another 58 clinics in other locations. If you enrol for this study, it would be best to choose a location near to reduce travelling time and costs."

"This study is no longer looking for patients to enroll. The trial was originally posted on May 8th, 2019 and was most recently edited on November 3rd, 2020. There are 2380 other trials currently underway for breast cancer and 866 for Sacituzumab Govitecan-hziy if you're interested in finding a different study to participate in."

"866 active clinical trials involving Sacituzumab Govitecan-hziy are ongoing, with the majority of these being Phase 3 trials. Most of these studies take place in Guangzhou, Guangdong; however, there are 37598 locations conducting research on this medication."

"Given that this is a Phase 3 trial with both efficacy and safety data, our team has determined that the risk level for Sacituzumab Govitecan-hziy is a 3."